1.52

1.94% -0.03

After Hours: 1.52

OKYO Pharma Limited (OKYO)

Overview News Price History Discussions Forecast

OKYO Pharma Limited stock is currently priced at $1.52, with a 24-hour trading volume of 11,905. It has seen a -1.94% decreased in the last 24 hours and a +7.80% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.52 pivot point. If it approaches the $1.47 support level, significant changes may occur.

Previous Close:

$1.55

Open:

$1.51

24h Volume:

11,905

Market Cap:

$50.52M

Revenue:

Net Income/Loss:

$-13.27M

P/E Ratio:

-9.2683

EPS:

-0.164

Net Cash Flow:

$-7.70M

1W Performance:

+4.11%

1M Performance:

+7.80%

6M Performance:

-10.59%

1Y Performance:

+0.00%

1D Range:

$1.4639

$1.58

52W Range:

$1.19

$2.95

OKYO Pharma Limited Stock (OKYO) Company Profile

Name

OKYO Pharma Limited

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

44 20 7495 2379

Address

14/15 Conduit St, Floor 4, London

Employee

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

OKYO's Discussions on Twitter

OKYO Pharma Limited Stock (OKYO) Latest News

OKYO Pharma (LON:OKYO) Stock Price Down 24.3% - Defense World

Defense World

OKYO Pharma Announces Participation in May 2024 Investor Conferences - Marketscreener.com

Marketscreener.com

OKYO Pharma Announces Participation in May 2024 Investor Conferences - Yahoo Finance

Yahoo Finance

OKYO Pharma Announces Participation in May 2024 Investor Conferences - Yahoo Finance

Yahoo Finance

OKYO Pharma to present at Dry Horizons Symposium - Proactive Investors USA

Proactive Investors USA

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

GlobeNewswire Inc.

OKYO Pharma Limited Stock (OKYO) Financials Data

OKYO Pharma Limited (OKYO) Net Income 2024

OKYO net income (TTM) was -$13.27 million for the quarter ending March 31, 2023, a -295.76% decrease year-over-year.

OKYO Pharma Limited (OKYO) Cash Flow 2024

OKYO recorded a free cash flow (TTM) of -$7.70 million for the quarter ending March 31, 2023, a -379.20% decrease year-over-year.

OKYO Pharma Limited (OKYO) Earnings per Share 2024

OKYO earnings per share (TTM) was -$0.164 for the quarter ending March 31, 2023, a +38.00% growth year-over-year.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.